002262 恩华药业
已收盘 08-20 15:00:00
资讯
新帖
简况
恩华药业（002262）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-19 06:08
恩华药业（002262）2026年中报简析：营收净利润同比双双增长
恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%
证券之星 · 08-18 17:28
恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%
恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验
美股速递 · 08-18 11:57
恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验
恩华药业(002262.SZ)：1类创新药NH302注射液获批开展临床试验
智通财经 · 08-18 11:55
恩华药业(002262.SZ)：1类创新药NH302注射液获批开展临床试验
图解恩华药业中报：第二季度单季净利润同比增长5.87%
证券之星 · 08-18 01:25
图解恩华药业中报：第二季度单季净利润同比增长5.87%
恩华药业（002262）披露2026年半年度报告，8月17日股价下跌1.32%
证券之星 · 08-17 22:34
恩华药业（002262）披露2026年半年度报告，8月17日股价下跌1.32%
股市必读：恩华药业（002262）8月4日董秘有最新回复
证券之星 · 08-05
股市必读：恩华药业（002262）8月4日董秘有最新回复
恩华药业：NH600001处于正常审核之中
证券之星 · 08-04
恩华药业：NH600001处于正常审核之中
恩华药业：公司创新药NH600001处于CDE正常审核之中
证券之星 · 07-22
恩华药业：公司创新药NH600001处于CDE正常审核之中
恩华药业获得发明专利授权：“(R)-3-[(苯并二氧戊环-4-基)氧基]-N,N-二甲基-3-(4-氟苯基)丙胺草酸盐的晶型及其制备方法和应用”
证券之星 · 07-15
恩华药业获得发明专利授权：“(R)-3-[(苯并二氧戊环-4-基)氧基]-N,N-二甲基-3-(4-氟苯基)丙胺草酸盐的晶型及其制备方法和应用”
股市必读：恩华药业（002262）7月8日董秘有最新回复
证券之星 · 07-09
股市必读：恩华药业（002262）7月8日董秘有最新回复
恩华药业：公司创新药NH600001乳状注射液目前处于CDE正常审核之中
证券之星 · 07-06
恩华药业：公司创新药NH600001乳状注射液目前处于CDE正常审核之中
恩华药业（002262）披露回购注销部分限制性股票减资暨通知债权人公告，6月30日股价下跌3.1%
证券之星 · 06-30
恩华药业（002262）披露回购注销部分限制性股票减资暨通知债权人公告，6月30日股价下跌3.1%
恩华药业：公司目前已经在越南实现非诺贝特、碳酸锂等原料药的销售
证券之星 · 06-30
恩华药业：公司目前已经在越南实现非诺贝特、碳酸锂等原料药的销售
股市必读：恩华药业（002262）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：恩华药业（002262）6月18日董秘有最新回复
恩华药业：公司一类创新药NH600001的审批进展一切正常顺利
证券之星 · 06-18
恩华药业：公司一类创新药NH600001的审批进展一切正常顺利
股市必读：恩华药业（002262）6月17日董秘有最新回复
证券之星 · 06-18
股市必读：恩华药业（002262）6月17日董秘有最新回复
恩华药业：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药
证券之星 · 06-17
恩华药业：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药
恩华药业(002262.SZ)拟出资2000万元参投医药行业投资基金
智通财经 · 06-12
恩华药业(002262.SZ)拟出资2000万元参投医药行业投资基金
恩华药业：该公司为控股子公司恩华连锁的子公司
证券之星 · 06-11
恩华药业：该公司为控股子公司恩华连锁的子公司
加载更多
公司概况
公司名称：
江苏恩华药业股份有限公司
所属行业：
医药制造业
上市日期：
2008-07-23
主营业务：
江苏恩华药业股份有限公司的主营业务是医药研发、生产和销售。公司的主要产品是原料药、麻醉类制剂、精神类制剂、神经类制剂。公司荣获“2026年度资信等级AAA”、“2026中国医药创新企业100强”、“2026化药研发实力20强”、“2026药品研发综合实力50强”等荣誉，恩华络康被纳入火炬企业库，恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。
发行价格：
5.68
{"stockData":{"symbol":"002262","market":"SZ","secType":"STK","nameCN":"恩华药业","latestPrice":22.79,"timestamp":1787209404000,"preClose":22.8,"halted":0,"volume":15745790,"delay":0,"changeRate":-0.0004,"floatShares":884000000,"shares":1016000000,"eps":1.0805,"marketStatus":"已收盘","change":-0.01,"latestTime":"08-20 15:00:00","open":23.2,"high":23.38,"low":22.46,"amount":360000000,"amplitude":0.0404,"askPrice":22.8,"askSize":276,"bidPrice":22.79,"bidSize":113,"shortable":0,"etf":0,"ttmEps":1.0805,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"adjPreClose":22.8,"symbolType":"stock","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":25.08,"lowLimit":20.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1015786583,"isCdr":false,"pbRate":2.76,"roa":"--","peRate":21.092087,"roe":"8.86%","epsLYR":1.05,"committee":-0.053797,"marketValue":23150000000,"turnoverRate":0.0178,"status":1,"floatMarketCap":20141000000},"requestUrl":"/m/hq/s/002262/","defaultTab":"news","newsList":[{"id":"2660859490","title":"恩华药业（002262）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2660859490","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660859490?lang=zh_cn&edition=full","pubTime":"2026-08-19 06:08","pubTimestamp":1787090887,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩华药业发布2026年中报。根据财报显示，恩华药业营收净利润同比双双增长。截至本报告期末，公司营业总收入32.18亿元，同比上升6.91%，归母净利润7.41亿元，同比上升5.74%。持有恩华药业最多的基金为华夏复兴混合A，目前规模为15.71亿元，最新净值2.816，较上一交易日上涨0.43%，近一年上涨24.88%。本文数据来源于恩华药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900004076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465980","title":"恩华药业(002262)6月30日股东户数5.34万户，较上期增加23.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465980","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660465980?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:28","pubTimestamp":1787045328,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩华药业披露，截至2026年6月30日公司股东户数为5.34万户，较3月31日增加1.03万户，增幅为23.8%。在化学制药行业个股中，恩华药业股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.64万户。从股价来看，2026年3月31日至2026年6月30日，恩华药业区间跌幅为14.61%，在此期间股东户数增加1.03万户，增幅为23.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU1064131003.USD","BK0070","LU1064130708.USD","LU2148510915.USD","BK0239","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194623670","title":"恩华药业：NMPA批准NH302注射液及NH130枸橼酸盐片临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1194623670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194623670?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:57","pubTimestamp":1787025428,"startTime":"0","endTime":"0","summary":"恩华药业宣布，其自主研发的NH302注射液与NH130枸橼酸盐片已获得国家药品监督管理局（NMPA）的临床试验批准。这一进展标志着公司在创新药物研发领域迈出了关键一步。两项药物均处于临床开发早期阶段，未来将针对特定适应症展开系统评估。此次获批不仅凸显了恩华药业在神经精神类药物领域的持续深耕，也为后续产品管线推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","002262","BK0188","LU2148510915.USD","BK0239","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660459730","title":"恩华药业(002262.SZ)：1类创新药NH302注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660459730","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660459730?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:55","pubTimestamp":1787025354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的1类化学药品NH302注射液的《药物临床试验批准通知书》，并将于近期开展临床试验。NH302为外周选择性Kappa受体激动剂。临床前试验结果表明：NH302对Kappa受体具有较强的激动活性，对多个疼痛动物模型均具有较好的镇痛效果，起效剂量低，作用时间长，镇静安全窗大，有望开发为具备明显临床优势的急性疼痛治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","MDTX","MEDX","06978","BK1161","BMED","BK0188","002262","BK0070","LNGR","LU2148510915.USD","LU1064131003.USD","BK1574","159992","IBBQ","BK0239","LU1064130708.USD","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431341","title":"图解恩华药业中报：第二季度单季净利润同比增长5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431341","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431341?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:25","pubTimestamp":1786987526,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业2026年中报显示，上半年度公司主营收入32.18亿元，同比上升6.91%；归母净利润7.41亿元，同比上升5.74%；扣非净利润7.46亿元，同比上升6.65%；其中2026年第二季度，公司单季度主营收入16.08亿元，同比上升7.25%；单季度归母净利润4.23亿元，同比上升5.87%；单季度扣非净利润4.28亿元，同比上升7.03%；负债率12.3%，投资收益3591.47万元，财务费用-564.84万元，毛利率73.86%。财报数据概要请见下图:本文数据来源于恩华药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660435999","title":"恩华药业（002262）披露2026年半年度报告，8月17日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660435999","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660435999?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:34","pubTimestamp":1786977261,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，恩华药业报收于21.67元，较前一交易日下跌1.32%，最新总市值为220.12亿元。该股当日开盘22.08元，最高22.08元，最低21.44元，成交额达2.03亿元，换手率为1.06%。近日，恩华药业披露《2026年半年度报告》。报告显示，本报告期营业收入为3,218,250,058.44元，同比增长6.91%；归属于上市公司股东的净利润为740,682,973.24元，同比增长5.74%；扣除非经常性损益后的净利润为745,987,159.61元，同比增长6.65%。经营活动产生的现金流量净额为280,408,381.42元，同比下降43.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700035816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0188","LU1064130708.USD","BK0239","BK0070","002262","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657379563","title":"股市必读：恩华药业（002262）8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657379563","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657379563?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:39","pubTimestamp":1785865150,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，恩华药业报收于21.91元，下跌1.44%，换手率1.15%，成交量10.21万手，成交额2.25亿元。董秘最新回复投资者： 请问董秘，NH600001发补完成了吗？董秘： 公司NH600001处于正常审核之中，相关工作在有序顺利推进。获得该创新药上市批件后，公司会及时进行公告。当日关注点交易信息汇总：8月4日主力资金净流入684.21万元，占总成交额3.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","002262","LU2148510915.USD","LU1064131003.USD","BK0188","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656362025","title":"恩华药业：NH600001处于正常审核之中","url":"https://stock-news.laohu8.com/highlight/detail?id=2656362025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656362025?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:45","pubTimestamp":1785833114,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，NH600001发补完成了吗？恩华药业回复：公司NH600001处于正常审核之中，相关工作在有序顺利推进。获得该创新药上市批件后，公司会及时进行公告。请关注公司公告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400027790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","LU2148510915.USD","BK0239","LU1064131003.USD","LU1064130708.USD","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653816753","title":"恩华药业：公司创新药NH600001处于CDE正常审核之中","url":"https://stock-news.laohu8.com/highlight/detail?id=2653816753","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653816753?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:33","pubTimestamp":1784709195,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业07月22日在投资者关系平台上答复投资者关心的问题。今天是7月21日，新药NH600001在6月8日六灯全灭的，到现在第30个工作日了，据说CDE结尾审批超过30个工作日属于重度超时。麻烦问一下，1、NH600001CDE审批环节是否一切顺利，有没有可能重度超时。恩华药业回复：公司创新药NH600001处于CDE正常审核之中，各项相关工作在有序顺利进行。获得该创新药上市批件后，公司会及时进行公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200033623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","06978","BK1574","002262","LU1064131003.USD","BK0239","BK1161","LU2148510915.USD","LU1064130708.USD","159992","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651545486","title":"恩华药业获得发明专利授权：“(R)-3-[(苯并二氧戊环-4-基)氧基]-N,N-二甲基-3-(4-氟苯基)丙胺草酸盐的晶型及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2651545486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651545486?lang=zh_cn&edition=full","pubTime":"2026-07-15 03:28","pubTimestamp":1784057294,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示恩华药业新获得一项发明专利授权，专利名为“-3-[氧基]-N,N-二甲基-3-丙胺草酸盐的晶型及其制备方法和应用”，专利申请号为CN202411527154.6，授权日为2026年7月14日。专利摘要：本发明涉及化合物3[氧基]N,N二甲基3丙胺草酸盐、晶型及其制备方法和应用和含有治疗有效量的该化合物的盐、晶型的药物组合物，及其在制备预防和/或治疗精神类疾病药物中的用途。今年以来恩华药业新获得专利授权14个，较去年同期增加了16.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500005319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0070","BK0188","002262","LU1064131003.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650900809","title":"股市必读：恩华药业（002262）7月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2650900809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650900809?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:26","pubTimestamp":1783531568,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，恩华药业报收于19.62元，下跌0.76%，换手率0.97%，成交量8.57万手，成交额1.69亿元。董秘最新回复投资者： 截止6月30日股东人数多少？由于“互动易”平台不属于公司信息的法定披露渠道，为严格遵守信息披露公平性原则，保障全体投资者信息获取一致，公司会在定期报告中披露股东人数和前十大股东持股情况。交易信息汇总资金流向7月8日主力资金净流出924.69万元；游资资金净流出534.72万元；散户资金净流入1459.41万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0070","LU2148510915.USD","LU1064130708.USD","BK0239","BK0188","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649232416","title":"恩华药业：公司创新药NH600001乳状注射液目前处于CDE正常审核之中","url":"https://stock-news.laohu8.com/highlight/detail?id=2649232416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649232416?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:27","pubTimestamp":1783333635,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业07月06日在投资者关系平台上答复投资者关心的问题。恩华药业回复：公司创新药NH600001乳状注射液目前处于CDE正常审核之中，各项相关工作进展顺利，力争早日获批上市。获得该创新药批件后，公司会及时进行公告。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600029471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0188","BK0070","159992","BK1161","LU1064131003.USD","LU2148510915.USD","BK1574","LU1064130708.USD","BK0239","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647552948","title":"恩华药业（002262）披露回购注销部分限制性股票减资暨通知债权人公告，6月30日股价下跌3.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647552948","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647552948?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:20","pubTimestamp":1782829236,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，恩华药业报收于18.75元，较前一交易日下跌3.1%，最新总市值为190.46亿元。近日，江苏恩华药业股份有限公司发布《关于回购注销部分限制性股票减资暨通知债权人的公告》。公告显示，公司于2026年6月12日召开第七届董事会第八次会议，审议通过《关于回购注销部分限制性股票的议案》。本次回购注销完成后，公司注册资本将由101,578.6583万元减少至101,297.1423万元。债权人自公告披露之日起45日内可要求公司清偿债务或提供担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000047096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0188","LU1064130708.USD","002262","BK0070","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647536285","title":"恩华药业：公司目前已经在越南实现非诺贝特、碳酸锂等原料药的销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2647536285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647536285?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:51","pubTimestamp":1782809477,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司目前在越南有哪些产品已经获批上市或实现销售？销售量是多少？恩华药业回复：公司目前已经在越南实现非诺贝特、碳酸锂等原料药的销售。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000030394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0070","BK0188","002262","FVNmain","LU1064131003.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645016200","title":"股市必读：恩华药业（002262）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645016200","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645016200?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:09","pubTimestamp":1782076154,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，恩华药业报收于18.69元，下跌0.11%，换手率1.13%，成交量9.96万手，成交额1.87亿元。董秘最新回复投资者： 尊敬的董秘，网传公司创新药发补要拖到明年了，是否属实？董秘： 公司一类创新药NH600001的审批进展一切正常顺利！有关公司新药开发的重要信息一切以公司公告为准。当日关注点交易信息汇总：6月18日主力资金净流出125.51万元，游资资金净流出118.27万元，散户资金净流入243.78万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","LU2148510915.USD","BK0239","LU1064131003.USD","LU1064130708.USD","002262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644830771","title":"恩华药业：公司一类创新药NH600001的审批进展一切正常顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2644830771","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644830771?lang=zh_cn&edition=full","pubTime":"2026-06-18 11:54","pubTimestamp":1781754843,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，网传公司创新药发补要拖到明年了，是否属实？谢谢！恩华药业回复：公司一类创新药NH600001的审批进展一切正常顺利！有关公司新药开发的重要信息一切以公司公告为准。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800018446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0188","BK0070","BK0239","LU2148510915.USD","002262","06978","159992","BK1574","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644572374","title":"股市必读：恩华药业（002262）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644572374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644572374?lang=zh_cn&edition=full","pubTime":"2026-06-18 02:01","pubTimestamp":1781719278,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，恩华药业报收于18.71元，下跌2.2%，换手率1.01%，成交量8.95万手，成交额1.68亿元。董秘： NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药，标志着公司从仿制药向自主创新药转型。该药品克服了依托咪酯抑制肾上腺皮质功能的副作用，同时保留了其起效快、苏醒平稳迅速、对呼吸循环影响小的优势。当日关注点交易信息汇总：6月17日主力资金净流出1527.19万元，占总成交额0.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800001584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","002262","LU1064131003.USD","BK0239","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644992317","title":"恩华药业：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2644992317","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644992317?lang=zh_cn&edition=full","pubTime":"2026-06-17 08:52","pubTimestamp":1781657529,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业06月17日在投资者关系平台上答复投资者关心的问题。恩华药业回复：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药，标志着公司从仿制药向自主创新药转型。该药品克服了依托咪酯抑制肾上腺皮质功能的副作用，同时保留了其起效快、苏醒平稳迅速、对呼吸循环影响小的优势。预计该产品获批上市后有望快速扩大销售规模，是公司未来增长的重要引擎之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700007404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1064131003.USD","BK0239","LU2148510915.USD","BK0070","06978","BK0188","159992","002262","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642260586","title":"恩华药业(002262.SZ)拟出资2000万元参投医药行业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2642260586","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642260586?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:33","pubTimestamp":1781264017,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩华药业(002262.SZ)发布公告，公司与上海德福福创咨询管理合伙企业(有限合伙)(以下简称“上海德福”)等合伙人共同发起设立上海德福创业投资基金合伙企业(有限合伙)(暂定名)(具体以市场监督管理部门登记的名称为准，以下简称“德福基金”或“合伙企业”), 并签署了《上海德福创业投资基金合伙企业(有限合伙)(暂定名)有限合伙协议》。德福基金目标认缴规模为人民币8亿元，公司作为有限合伙人，以自有资金出资人民币2000万元。预计占合伙企业目标认缴规模的2.50%。合伙企业主要投资于创新药和生物技术、创新器械、生命科学高端仪器设备、医疗人工智能等领域的企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","BK0188","LU1064130708.USD","002262","BK0070","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642401069","title":"恩华药业：该公司为控股子公司恩华连锁的子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2642401069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642401069?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:07","pubTimestamp":1781161635,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问：2025年8月1日，你们成立了艾之嘉宠物用品有限公司，看了你们注册了平台网店，但是卖的产品极少。你们是打算卖宠物食品还是药品？药品主要是精麻类药物呢，还是会开发生产其他药类？目前该方向进展如何？恩华药业回复：答：该公司为控股子公司恩华连锁的子公司，目前主要做宠物食品零售业务，以后会逐步涉足宠物药品零售，暂时不会开发生产其它宠物药品，该公司尚处于试运营阶段。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100018693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","002262","BK0188","LU2148510915.USD","BK0239","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787229078044,"stockEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":0.079},{"period":"3month","weight":0.1214},{"period":"6month","weight":-0.0186},{"period":"1year","weight":-0.0741},{"period":"ytd","weight":-0.0361}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":0.0259},{"period":"3month","weight":-0.0448},{"period":"6month","weight":-0.046},{"period":"1year","weight":0.0448},{"period":"ytd","weight":-0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恩华药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"53378人(较上一季度增加23.80%)","perCapita":"16556股","listingDate":"2008-07-23","address":"江苏省徐州市鼓楼区经济技术开发区杨山路18号","registeredCapital":"101578万元","survey":" 江苏恩华药业股份有限公司的主营业务是医药研发、生产和销售。公司的主要产品是原料药、麻醉类制剂、精神类制剂、神经类制剂。公司荣获“2026年度资信等级AAA”、“2026中国医药创新企业100强”、“2026化药研发实力20强”、“2026药品研发综合实力50强”等荣誉，恩华络康被纳入火炬企业库，恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。","listedPrice":5.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩华药业,002262,恩华药业股票,恩华药业股票老虎,恩华药业股票老虎国际,恩华药业行情,恩华药业股票行情,恩华药业股价,恩华药业股市,恩华药业股票价格,恩华药业股票交易,恩华药业股票购买,恩华药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}